TorreyPines Therapeutics, Inc. has initiated a Phase I clinical trial for NGX426, the company’s novel oral therapy intended for the treatment of migraine and chronic pain conditions such as neuropathic pain.
The double-blind, placebo-controlled, single ascending dose Phase 1 trial will evaluate the safety, tolerability and pharmacokinetics of NGX426 in 30 healthy adult male and female volunteers at one center in the United States.
"The start of this clinical trial moves TorreyPines closer to its goal of building a strong, non-narcotic pain franchise to address the diverse and unmet needs of many pain sufferers," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines.
"By developing parenteral and oral routes of administration, we will have the ability to target multiple segments of the chronic pain market. We look forward to advancing our clinical programs for both NGX426 and tezampanel."
NGX426 is an oral prodrug of tezampanel, TorreyPines’ parenteral product candidate in development for migraine. As shown in preclinical studies, NGX426, following oral administration, is rapidly converted to tezampanel.
Tezampanel and NGX426 are AMPA/kainate (AK) receptor antagonists that potentially offer a non-opioid, non-vascular approach to the management of migraine and other persistent pain states.
Source: TorreyPines Therapeutics, Inc.
.jpg)
Comment Preview